

2 **2019 in Jilin Province, China**

3 **Running title: Assessing countermeasures to control COVID-19**

4 **Qinglong Zhao[#]**, Jilin Provincial Center for Disease Control and Prevention, Changchun, 130062, Jilin

5 Province, People's Republic of China. Email: jlcdezql@126.com

6 **Yao Wang[#]**, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of

7 Public Health, Xiamen University, Xiamen City 361102, Fujian Province, People's Republic of China;

8 Email: 812304436@qq.com

9 **Meng Yang[#]**, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of

10 Public Health, Xiamen University, Xiamen City 361102, Fujian Province, People's Republic of China;

11 Email: yangmeng0531@163.com

12 **Meina Li**, The first Hospital of Jilin University, Changchun 130021, Jilin Province, People's Republic

13 of China; Email: lmn_1982@yeah.net

14 **Zeyu Zhao**, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of

15 Public Health, Xiamen University, Xiamen City 361102, Fujian Province, People's Republic of China;

16 Email: 381597586@qq.com

17 **Xinrong Lu**, Jilin Provincial Center for Disease Control and Prevention, Changchun, 130062, Jilin

18 Province, People's Republic of China. Email: luxr78@foxmail.com

19 **Bo Shen**, Jilin Provincial Center for Disease Control and Prevention, Changchun, 130062, Jilin

20 Province, People's Republic of China; Email: 76000471@qq.com

21 **Bo Luan**, Jilin Provincial Center for Disease Control and Prevention, Changchun, 130062, Jilin

22 Province, People's Republic of China; Email: 443023974@qq.com

23 **Yifei Zhao**, Jilin Provincial Center for Disease Control and Prevention, Changchun, 130062, Jilin

24 Province, People's Republic of China; Email: 1741153413@qq.com

25 **Bonan Cao**, Jilin Provincial Center for Disease Control and Prevention, Changchun, 130062, Jilin

26 Province, People's Republic of China; Email: cbanays@163.com

27 **Laishun Yao**, Jilin Provincial Center for Disease Control and Prevention, Changchun, 130062, Jilin

28 Province, People's Republic of China; Email: yls@jlcde.com.cn

29 **Benhua Zhao**, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of

30 Public Health, Xiamen University, Xiamen City 361102, Fujian Province, People's Republic of China;

31 Email: benhuazhao@163.com

32 **Yanhua Su***, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of

33 Public Health, Xiamen University, Xiamen City 361102, Fujian Province, People's Republic of China;

34 Email: suyanhua813@xmu.edu.cn

35 **Tianmu Chen***, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School

36 of Public Health, Xiamen University, Xiamen City 361102, Fujian Province, People's Republic of

37 China; Email: 13698665@qq.com

38 **#These authors contributed equally to this study.**

39

40 ***Correspondence:**

41 **Tianmu Chen**

42 State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health,

43 Xiamen University

44 4221-117 South Xiang'an Road, Xiang'an District, Xiamen City, Fujian Province, People's Republic of

45 China

46 Email: chentianmu@xmu.edu.cn, 13698665@qq.com

47 **Yanhua Su,**

48 State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health,

49 Xiamen University

50 4221-117 South Xiang'an Road, Xiang'an District, Xiamen City, Fujian Province, People's Republic of

51 China

52 Email: suyanhua813@xmu.edu.cn

53

54

55

56

57

58 **Abstract**

59 **Objective:** This study aimed to calculate the transmissibility of coronavirus disease 2019 (COVID-19),
60 and to evaluate the effectiveness of countermeasures to control the disease in Jilin Province, China.

61 **Methods:** The data of reported COVID-19 cases were collected, including imported and local cases
62 from Jilin Province as of March 14, 2019. A Susceptible–Exposed–Infectious–Asymptomatic–
63 Recovered (SEIAR) model was developed to fit the data, and the effective reproduction number (R_{eff})
64 was calculated at different stages in the province. Finally, the effectiveness of the countermeasures was
65 assessed.

66 **Results:** A total of 97 COVID-19 infections were reported in Jilin Province, among which 45 were
67 imported infections (including one asymptomatic infection) and 52 were local infections (including
68 three asymptomatic infections). The model fit well with the reported data ($R^2 = 0.593$, $P < 0.001$). The
69 R_{eff} of COVID-19 before and after February 1, 2020 was 1.64 and 0.05, respectively. Without the
70 intervention taken on February 1, 2020, the predicted cases would reach a peak of 177011 on October
71 22, 2020 (384 days from the first case), and 17129367 cases would be reported until the end of the
72 outbreak (on October 9, 2021), with a total attack rate of 63.66%. These results revealed that the
73 interventions implemented in Jilin Province had reduced more than 99.99% cases.

74 **Conclusions:** COVID-19 has a moderate transmissibility in Jilin Province, China. The interventions
75 implemented in the province had great effectiveness.

76 **Keywords:** COVID-19, China, epidemic, disease countermeasures, disease transmissibility

77

78 **Background**

79 Coronavirus disease 2019 (COVID-19) is caused by the novel coronavirus with typical symptoms
80 of fever, dry cough, shortness of breath, and fatigue[1, 2]. The incubation period of COVID-19 was
81 reported to be 3-7 days, with a minimum of one day and a maximum of 14 days. Nucleic acid detection
82 and genome sequencing have commonly been conducted with pharyngeal swabs, sputum, alveolar
83 lavage fluid, feces, and other samples from patients to detect COVID-19 virus[3-7]. It has been
84 reported that COVID-19 can be transmitted person-to-person, with the main transmission methods
85 being air transmission and contact transmission[8-12]. Therefore, persons can be infected by exposure
86 to the outside environment and the virus can be spread by inhaling COVID-19 droplets or aerosols that
87 are exhaled into the air by the source of the infection, or people can be infected by contact with
88 virus-contaminated items.

89 Due to its diverse transmission routes and strong transmissibility, COVID-19 has become a global
90 epidemic in a short period of time. The World Health Organization (WHO) announced that this
91 epidemic was a public health emergency of international concern. As of April 8th, more than 200
92 countries and regions have experienced COVID-19 outbreaks. Furthermore, the number of confirmed
93 cases worldwide has become as high as 1,353,361 and there have been 79,235 cumulative deaths[13].
94 According to the report of the Chinese Health Commission, as of April 9, a total of 81,865 confirmed
95 cases and a total of 3,335 deaths in China have been reported[14]. According to data from the Jilin
96 Provincial Center for Disease Control and Prevention, a total of 98 cases with one death were
97 reported[15]. On January 25, Jilin Province launched the Public health events level I emergency
98 response, and took measures to control the non-resident population, such as isolation and observation at

99 home, disinfection and sterilization, temperature measurement screening, wearing masks, etc.[16].
100 Since then, the epidemic situation in Jilin Province has been checked. Although the severity of the
101 domestic epidemic has declined, the problems of imported cases and asymptomatic cases have still
102 been very serious.

103 At present, several studies of COVID-19 transmission models have been reported to evaluate the
104 transmissibility of COVID-19 virus and predict the future epidemic situation[8, 17-19]. However, the
105 more important issue at present is to consider asymptomatic infections when designing models.
106 Asymptomatic infection refers to cases who tested positive for COVID-19 in the laboratory tests, yet
107 had mild or even no symptoms. Asymptomatic cases can potentially transmit the virus to others. It is
108 predicted that at least 59% of infectious cases have not been tested[20]. Therefore, ignorance of
109 asymptomatic infections may have a greater impact on the effectiveness of the model, while at the
110 same time, traditional infectious disease models were built under the condition that the disease is
111 allowed to develop[2, 8, 17, 18, 21-25]. However, China declared a first-level health emergency in the
112 early stage of the outbreak, and with a strict supervision system and the high degree of cooperation of
113 the people, a series of prevention and control measures, such as wearing masks, restricting travel, and
114 suspending work and school were implemented. In this study, our COVID-19 model was established
115 with comprehensive consideration of most of the possibilities of comprehensive prevention and control
116 measures that exist. Moreover, there is no domestic province that can be used to construct a dynamic
117 model of the spread of COVID-19 according to the local population characteristics and epidemic
118 distribution. Hence, the transmissibility of COVID-19 in Jilin Province is still unclear and the effect of
119 current prevention and control measures on the epidemic still needs to be explored. This study focused

120 on the susceptible–exposed–infectious–asymptomatic–recovered (SEIAR) model based on the
121 distribution of outbreaks in Jilin Province. The various parameters in the model were calculated based
122 on the actual cases obtained, so it is closer to the real situation; the fit of the model to the actual data
123 was explored, the effectiveness of current prevention and control measures was evaluated, and the
124 progress of the epidemic without measures was predicted.

125

126 **Methods**

127 **Data collection**

128 The case information collected in this article was provided by the Jilin Provincial Center for
129 Disease Control and Prevention, including onset date, diagnosis date, date of contact with related cases,
130 disease severity, and laboratory diagnosis of different case types. In addition, the permanent population
131 of Jilin Province comes from the “Jilin Statistical Yearbook.”

132 **Transmission model**

133 According to the COVID-19 propagation dynamic model that this team has built[26], the SEIAR
134 model of “person-to-person,,” secondary cases of COVID-19 were only prevalent in Jilin Province for
135 27 days. The natural birth rate and mortality rate of the population during this period were negligible.
136 Therefore, on this basis, we have improved the model by excluding the natural birth and natural death
137 of various populations to construct a SEIAR model of COVID-19 in Jilin Province. The model is based
138 on the following assumptions:

139 (1) The model divides the population into five categories: susceptible (S), exposed (E),

140 infectious (I), asymptomatic (A), and removed (R).

141 (2) Both I and A are infectious, and A 's transmissibility is k times that of I ($0 < k < 1$). S may be
142 infected when exposed to I and A , and the infection rate coefficient is β . Therefore, at time t , the
143 infected S is $\beta S(I + A)$.

144 (3) Among E , the proportion of those who develop asymptomatic infections is p , the incubation
145 period is $1/\omega$, and the incubation period is $1/\omega'$. Then at time t , there is $p\omega'E$ persons in E who
146 develops into A , and $(1-p)\omega E$ persons become I .

147 (4) I from the onset to admission is $1/\gamma$ days, that is, there are γI admitted to the hospital in
148 unit time. Therefore, at time t , there are γI people in I who change to movers. The case fatality rate of I
149 is f , so at time t , fI people die in I .

150 (5) A has an infectious period of $1/\gamma'$, that is, γ' persons in A escape from the infectious period
151 in unit time. Therefore, at time t , there are $\gamma' A$ people in A who are transformed into movers.

152 Therefore, the framework of the SEIAR model with the natural birth rate and mortality rate of the
153 population removed is shown in [Figure 1](#). The differential equations of the model are as follows:

$$\begin{aligned} dS / dt &= -\beta S(I + kA) \\ dE / dt &= \beta S(I + kA) - p\omega'E - (1-p)\omega E \\ dI / dt &= np + (1-p)\omega E - \gamma I \\ dA / dt &= p\omega'E - \gamma' A \\ dR / dt &= \gamma I + \gamma' A \end{aligned}$$

155

156 Parameter estimation

157 The total number of susceptible people comes from the number of permanent residents in Jilin

158 Province recorded in the Jilin Statistical Yearbook. According to the actual incidence characteristics of
159 COVID-19 in Jilin Province, the cases were divided into two types: imported cases as the source of
160 infection and secondary cases used as the actual data to fit the model. According to the trend of the
161 secondary cases over time, using February 1 as the cut-off point, the time distribution curve of the
162 continuation of cases was divided into two sections and fitted by the model separately, and the β value
163 in different time periods were obtained (β_1 and β_2).

164 According to previous research by our team, the transmissibility of asymptomatic infections is the
165 same as for infections, $k = 1$. There were four asymptomatic infections among 97 cases in Jilin
166 Province, that is, the proportion of asymptomatic infections was 0.04. To calculate the time interval
167 from infection to symptom onset in all cases in Jilin Province, except for asymptomatic infections, the
168 median was calculated as 10. Checking the previous literature showed that the COVID-19 incubation
169 period of asymptomatic infections is the same as that of infections[26], therefore, $\omega = \omega' = 0.1$. The
170 time interval from the onset to admission of infectious cases in Jilin Province was calculated, and the
171 median was 3. Because asymptomatic infections are mostly admitted to hospital for isolation treatment
172 for intensive contacts the infections, and the proportion of asymptomatic infections in Jilin Province is
173 small, the period of infection of asymptomatic infections is similar to that of infections. Therefore, $\gamma =$
174 $\gamma' = 0.33$. According to the statistics of COVID-19 in Jilin Province, there was only one death in all
175 patients, so in the COVID-19 model in Jilin Province, the mortality rate f was negligible, that is, $f = 0$.
176 The model parameter values and methods are shown in [Table 1](#).

177 **Transmissibility of COVID-19**

178 Under ideal circumstances, the basic reproduction number (R_0) can be used to quantify the

179 transmissibility of COVID-19[26-29], R_0 is the number of cases where the source of infection directly
180 spread during the infection period. Comparing the R_0 value with 1 can be used as an index to evaluate
181 whether the disease is prevalent. If the evaluated disease does not spread in a natural state, such as the
182 application of isolation, vaccines, and other interventions, R_0 cannot reflect the actual spread of the
183 disease. At this time, an effective reproduction number (R_{eff}) is needed to represent transmissibility.
184 Based on previous research[30-32], R_{eff} can be expressed by the following equation:

$$185 \quad \lim_{dr \rightarrow \infty} R_{eff} = \beta S \left(\frac{1-p}{\gamma+f} + \frac{\kappa p}{\gamma'} \right)$$

186 At the same time, because the mortality rate of COVID-19 in Jilin Province is close to 0, the equation
187 can be simplified to:

$$188 \quad R_{eff} = \beta S \left(\frac{1-p}{\gamma} + \frac{\kappa p}{\gamma'} \right)$$

189 **Simulation method and statistical analysis**

190 The software Berkeley Madonna 8.3.18 was used to model the actual cases, and the fourth-order
191 Runge-Kutta method was used to solve the differential equations. Curve estimation in SPSS 20.0 was
192 used to compare the fitted data with the actual data, and observe the P and R^2 values to judge the
193 goodness of fit.

194

195 **Results**

196 **Epidemiological characteristics**

197 As of March 14, a total of 97 COVID-19 infections, including 45 imported infections (including

198 one asymptomatic infection) and 52 secondary infections (including three asymptomatic infections),
199 were reported. The first case in Jilin Province was an imported case whose onset date was January 12,
200 2020, while the latest case was a secondary case whose onset date was February 9, 2020. The peak date
201 of the incidence of imported cases was January 22, and the peak of local cases was February 1. The
202 stacked histogram of changes is shown in [Figure 2](#).

203 Regarding the gender breakdown ([Figure 3](#)), there were 56 males and 41 females. Among male
204 and female cases, normal cases predominated, accounting for 54% and 49% of all case types,
205 respectively. In descending order, these were followed by mild, severe, and critical cases.

206 The proportion of disease severity of different age groups was analyzed ([Figure 4](#)). The age of
207 onset was concentrated between 20-59 years, accounting for about 80.41% of the total number of
208 patients. Among them, the proportion of mild cases in the 40-49 age group was 56%, the proportion of
209 normal cases in the 30-39 age group was 73.33%, and the proportion of severe cases in the 80-89 age
210 group was 33.33%, the proportion of critical cases in the 70-79 age group was up to 20%. The
211 proportion of normal cases was highest in different age groups, and the number of cases decreased as
212 the severity of the disease increased.

213 **Model fitting and calculation of transmissibility**

214 According to the comparison between the model fitting curve and the actual secondary cases
215 curve ([Figure 5](#)), the degree of fitness was good. At the same time, the goodness-of-fit test results
216 showed that the difference between secondary cases fitted by the model and the actual secondary cases
217 was statistically significant ($R^2 = 0.593$, $P < 0.001$). The values of β_1 and β_2 obtained by the model
218 fitting were brought into the formula of the effective reproduction number; the effective reproduction

219 number of COVID-19 in Jilin Province before February 1 was 1.64, the effective reproduction number
220 of COVID-19 in Jilin Province after February 1 was 0.05, and the transmissibility decreased by
221 96.95%.

222 It is known that after February 1, the incidence of COVID-19 showed a downward trend, and the
223 last case occurred on February 19 (Figure 2). If no intervention measures had been taken after the onset
224 of new coronary pneumonia, the model can fit the curve of the future incidence in this scenario (Figure
225 6). Therefore, if no measures had been taken, the model predicted that the incidence on February 19
226 would have been 13 cases, while the actual incidence on that date was one case. Therefore, the
227 comprehensive interventions reduced the incidence by 92.31%. If the epidemic situation had been
228 allowed to continue, the incidence curve would resemble a bell shape, and it would reach a peak of
229 incidence on October 22, 2020 (284 days from the first case), with 177011 cases on that day, and the
230 epidemic would last for 22 months. At the same time, the forecast can also predict the condition of
231 onset at the end of each month in the near future (Table 2). Without intervention taken on February 1,
232 2020, a total of 17,129,367 cases would have been reported until the end of the outbreak (on October 9,
233 2021), with a total attack rate of 63.66%. These results revealed that the interventions implemented in
234 Jilin Province reduced the number of cases by more than 99.99%.

235 In addition, this study predicts the epidemic curve and peak incidence of COVID-19 after taking
236 measures at different time points (Figure 7). The following figure shows the future incidence curve
237 when the number of days from the first case varies (175 days, 200 days, 225 days, 250 days, 275 days,
238 300 days, 325 days, 350 days, 375 day). The trend turns into a gradual decline in the curve fitting
239 figure. The prevalence of measures taken at different time points shows that the sooner measures are

240 taken, the more easily the epidemic can be controlled, the lower the peak number of outbreaks, the
241 earlier the end of the outbreak, and the lower the cumulative number of outbreaks (Table 3).

242

243 Discussion

244 Based on the epidemic situation of COVID-19 in Jilin Province, we constructed a transmission
245 dynamics model that accords with the population characteristics of Jilin province. Furthermore, based
246 on the collection of 97 cases as of March 14, the true parameters of Jilin Province were calculated.
247 Using imported cases as the source of infection, the model calculates fitted secondary cases based on
248 local secondary cases. Therefore, from the design of the model, the calculation of parameters and the
249 fitting of data, it is more in line with the actual situation of Jilin Province, and the transmissibility index
250 is more real.

251 According to the temporal distribution of COVID-19 in Jilin Province (Figure 2), the imported
252 cases in Jilin reached a peak on January 22nd, and decreased after January 23rd. Since January 31st,
253 the imported cases have remained at a low level. On January 23, the city was closed in Wuhan. At the
254 same time, Jilin Province implemented measures of screening and isolation for outsiders. This time
255 coincided with the period of decline in imported cases, indicating that the above interventions had
256 obvious effects. On January 31st 2020, the measures of having a flexible working system and fewer
257 meetings were implemented. Personnel were required to wear masks when entering or leaving public
258 places. From Figure 2, we can see that since February 1st, the number of secondary cases and daily
259 actual incidence has been decreasing. Since January 31, 2020, the implementation time of intervention
260 measures such as reducing travel and wearing masks has been consistent with the incidence decline

261 time. This shows that the above intervention measures were effective in this period.

262 The clinical disease types of COVID-19 in Jilin are the most common cases[33], and are
263 consistent with the distribution of clinical types in the whole country. This shows that most cases are
264 mild and easily treated by patients as common influenza. For this reason, it has not been easy to
265 investigate who infected persons have had close contact with. Therefore, a large number of sources of
266 infection were not effectively isolated in the external environment at the early stage of the disease and
267 at the early stage of the epidemic, which was the main reason for the public response delay in the early
268 stage of the outbreak.

269 The age of onset of COVID-19 in Jilin was mainly between 20-59 years old. Among these cases,
270 people aged 30-49 years most commonly had mild and normal cases[34]. Therefore, in young adults,
271 the prognosis of the disease is better and mortality is low.

272 In this study, according to the time distribution characteristics of the epidemic curve of COVID-19
273 in Jilin Province, taking February 1st as the time cut-off point, the data were divided into two sections
274 to fit the secondary cases, and the fitting effect was better ($R^2 = 0.593$, $P < 0.001$). According to the
275 fitting results, the effective reproduction number of the first stage (before February 1st) was 1.64,
276 indicating that the infection source of COVID-19 could infect about two people during the infectious
277 period. If intervention had not been taken in time to allow the disease to progress naturally, COVID-19
278 in Jilin would have continued to spread widely. The effective reproduction number in the second stage
279 (after February 1st) was 0.05, that is, the infection source of a new coronavirus could infect 0.05 people
280 during the infectious period, meaning that the epidemic situation had been controlled by this stage. The
281 comprehensive intervention measures in Jilin Province reduced the transmissibility of COVID-19 by

282 96.95%.

283 Combined with a series of related measures since the outbreak of the epidemic in Jilin Province, a
284 series of related measures were launched on January 23rd, including closing tourist spots, suspending
285 business operations, ensuring good disinfection and ventilation in public places, and banning wild
286 animal trade. On January 25th, 2020, the Jilin provincial government launched a public health events
287 level I emergency response, strengthened the investigation of non-native people and isolated non-native
288 people at home, strengthened body temperature testing, implemented disinfection and sterilization
289 measures, encouraged wearing of masks, and strengthened the management of large scale activities.
290 From January 31, 2020, the unit flexible working system was implemented to reduce the number of
291 meetings and personnel input. The above measures were effective in the second stage of COVID-19,
292 and transmissibility was reduced by 96.95%. Additionally, by the deadline (February 19), the actual
293 number of secondary cases had been reduced by 92.31%, so that the epidemic could be controlled. If
294 Jilin had not taken measures and had allowed the disease to develop before February 1st, the
295 prevalence of COVID-19 would have continued to spread in the province. The peak would have been
296 reached by October 22, 2020, with the number of cases on that day being 177011. The epidemic would
297 have continued to be prevalent for 22 months, with a cumulative number of 17129367 cases, and an
298 attack rate during the epidemic of 63.66%. Therefore, a series of prevention and control measures
299 formulated and implemented in Jilin Province effectively controlled the progress of the COVID-19
300 epidemic, and, as much as possible, helped avoid an interpersonal epidemic.

301 **Limitations**

302 The parameters in this research model were calculated based on the actual data of Jilin Province,

303 so the quality of the data is high. However, the small number of actual illnesses in Jilin Province would
304 have had a certain impact on the calculation of the model. There were only four asymptomatic
305 infections in the data obtained, which reduced the reliability of the proportion estimation of
306 asymptomatic infections in Jilin Province. At present, studies have shown that asymptomatic infections
307 also have transmissibility, and they are not easy to find and isolate, which promotes the spread of
308 disease and the epidemic. This model takes into account the effect of asymptomatic infection in the
309 population. Therefore, error in the proportion of asymptomatic infections may cause the prediction
310 results to deviate from the actual situation.

311 In this study, the reciprocal of the incubation period calculated using the actual data of the
312 COVID-19 in Jilin Province was a parameter in the model, so the accuracy of the incubation period
313 calculation can also affect the model's prediction. The incubation period of COVID-19 is 3-7 days[35],
314 and the incubation period of the disease calculated in this study was 10 days in Jilin Province. The
315 reason may be that the time of contact with the first case is uncertain, and there are some cases with
316 unclear contact time, such as repeated or continuous contact. Therefore, it is necessary to clarify the
317 activity trajectory of secondary cases, or how long susceptible persons have the ability to infect others
318 after being exposed to the source of infection. This is also a direction for exploration in future research.

319 In accordance with the epidemic trend of the disease, this study fitted the actual number of
320 secondary cases in two stages. Additionally, the transmissibility of COVID-19 after February 1 was
321 evaluated, and the effectiveness of preventive measures was verified. However, this article evaluated
322 comprehensive prevention and control measures, and did not evaluate certain specific measures. It is
323 not possible to determine which specific measure produced an effect. To solve this problem, it will be

324 necessary to establish a model that considers separate prevention and control measures. However, the
325 specific implementation time and completion status of each measure are difficult to determine, so this
326 situation is difficult to achieve.

327 **Conclusions**

328 COVID-19 had moderate transmissibility in Jilin Province, China. The interventions implemented
329 in the province had great effectiveness.

330

331

332

333 **Abbreviations**

334 COVID-19: coronavirus disease 2019; SEIAR: susceptible – exposed – infectious – asymptomatic –
335 recovered.

336 **Ethics approval and consent to participate**

337 This effort of disease control was part of CDC's routine responsibility in Jilin Province, China.

338 Therefore, institutional review and informed consent were waived by the Ethics Committee of Jilin

339 Provincial Center for Disease Control and Prevention. All data analyzed were anonymized.

340 **Consent for publication**

341 Not applicable.

342 **Availability of data and materials**

343 The datasets used and analyzed during the current study are available from Dr. Qinglong Zhao
344 (jlcdcqzql@126.com) on reasonable request.

345 **Competing interests**

346 The authors declare that they have no competing interests.

347 **Funding**

348 This study was partly supported by the Bill & Melinda Gates Foundation (INV-005834), the Science
349 and Technology Program of Fujian Province (No: 2020Y0002), and the Xiamen New Coronavirus
350 Prevention and Control Emergency Tackling Special Topic Program (No: 3502Z2020YJ03).

351 **Authors' contributions**

352 TC, QL, and YS designed research; QZ, ML, XL, BS, BL, YZ, BC, and LY collected the data; YW, MY,
353 ZZ, BZ, YS and TC analyzed the data; TC, YW, MY, and QZ wrote the manuscript. All authors read
354 and approved the final manuscript.

355 **Acknowledgements**

356 Not applicable.

357

358

359 **References:**

360 1. Hui DS, E IA, Madani TA, Ntoumi F, Kock R, Dar O, Ippolito G, McHugh TD, Memish ZA,
361 Drosten C, Zumla A, Petersen E: **The continuing 2019-nCoV epidemic threat of novel**

- 362 **coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan,**
363 **China.** *International journal of infectious diseases : IJID : official publication of the*
364 *International Society for Infectious Diseases* 2020, **91**:264-266.
- 365 2. Read JM, Bridgen JRE, Cummings DAT, Ho A, Jewell CP: **Novel coronavirus 2019-nCoV:**
366 **early estimation of epidemiological parameters and epidemic predictions.** *medRxiv*, 2020.
- 367 3. Benvenuto D, Giovanetti M, Ciccozzi A, Spoto S, Angeletti S, Ciccozzi M: **The 2019-new**
368 **coronavirus epidemic: Evidence for virus evolution.** *Journal of medical virology* 2020,
369 **92**(4):455-459.
- 370 4. Dong N, Yang X, Ye L, Chen K, Chan EW-C, Yang M, Chen S: **Genomic and protein**
371 **structure modelling analysis depicts the origin and infectivity of 2019-nCoV, a new**
372 **coronavirus which caused a pneumonia outbreak in Wuhan, China.** . *bioRxiv* 2020.
- 373 5. The L: **Emerging understandings of 2019-nCoV.** *Lancet (London, England)* 2020,
374 **395**(10221):311.
- 375 6. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, Si H-R, Zhu Y, Li B, Huang C-L,
376 Chen H-D, Chen J, Luo Y, Guo H, Jiang R-D, Liu M-Q, Chen Y, Shen X-R, Wang X, Zheng
377 X-S, Zhao K, Chen Q-J, Deng F, Liu L-L, Yan B, Zhan F-X, Wang Y-Y, Xiao G-F, Shi Z-L:
378 **Discovery of a novel coronavirus associated with the recent pneumonia outbreak in**
379 **humans and its potential bat origin.** *bioRxiv* 2020.
- 380 7. Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Hu Y, Song Z-G, Tao Z-W, Tian J-H, Pei Y-Y, Yuan
381 M-L, Zhang Y-L, Dai F-H, Liu Y, Wang Q-M, Zheng J-J, Xu L, Holmes EC, Zhang Y-Z:

- 382 **Complete genome characterization of a novel coronavirus associated with severe human**
383 **respiratory disease in Wuhan, China.** *bioRxiv* 2020.
- 384 8. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY,
385 Xing X, Xiang N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Liu M, Tu W, Chen C, Jin L,
386 Yang R, Wang Q, Zhou S, Wang R, Liu H, Luo Y, Liu Y, Shao G, Li H, Tao Z, Yang Y, Deng Z,
387 Liu B, Ma Z, Zhang Y, Shi G, Lam TTY, Wu JT, Gao GF, Cowling BJ, Yang B, Leung GM,
388 Feng Z: **Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected**
389 **Pneumonia.** *The New England journal of medicine* 2020, **382**(13):1199-1207.
- 390 9. Tang JW, Tambyah PA, Hui DSC: **Emergence of a novel coronavirus causing respiratory**
391 **illness from Wuhan, China.** *The Journal of infection* 2020, **80**(3):350-371.
- 392 10. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T,
393 Zhang X, Zhang L: **Epidemiological and clinical characteristics of 99 cases of 2019 novel**
394 **coronavirus pneumonia in Wuhan, China: a descriptive study.** *Lancet (London, England)*
395 2020, **395**(10223):507-513.
- 396 11. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan
397 F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W: **A Novel Coronavirus from Patients with**
398 **Pneumonia in China, 2019.** *The New England journal of medicine* 2020, **382**(8):727-733.
- 399 12. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR: **Severe acute respiratory syndrome**
400 **coronavirus 2 (COVID-19) and coronavirus disease-2019 (COVID-19): The epidemic**
401 **and the challenges.** *International journal of antimicrobial agents* 2020, **55**(3):105924.

- 402 13. **Coronavirus disease 2019 (COVID-19) Situation Report – 79**
403 [https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200408-sitrep-79-covid-19.pdf?sfvrsn=4796b143_6]
404
- 405 14. [<http://www.nhc.gov.cn/xcs/yqtb/202004/fa7bb40a7fbf4b2c8f3989d512fe5b77.shtml>]
406
- 407 15. [http://www.jl.gov.cn/szfzt/jlzd/yqtb/202004/t20200409_7064800.html]
408
- 409 16. [<https://baijiahao.baidu.com/s?id=1656717951737450858&wfr=spider&for=pc>]
410
- 411 17. Zhao S, Musa SS, Lin Q, Ran J, Yang G, Wang W, Lou Y, Yang L, Gao D, He D, Wang MH:
412 **Estimating the Unreported Number of Novel Coronavirus (2019-nCoV) Cases in China**
413 **in the First Half of January 2020: A Data-Driven Modelling Analysis of the Early**
414 **Outbreak.** *Journal of clinical medicine* 2020, 9(2).
- 415 18. Wu JT, Leung K, Leung GM: **Nowcasting and forecasting the potential domestic and**
416 **international spread of the 2019-nCoV outbreak originating in Wuhan, China: a**
417 **modelling study.** *Lancet (London, England)* 2020, 395(10225):689-697.
418
- 419 19. Zhao S, Lin Q, Ran J, Musa SS, Yang G, Wang W, Lou Y, Gao D, Yang L, He D, Wang MH:
420 **Preliminary estimation of the basic reproduction number of novel coronavirus**
421 **(2019-nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase of**
422 **the outbreak.** *International journal of infectious diseases : IJID : official publication of the*
423 *International Society for Infectious Diseases* 2020, 92:214-217.
- 424 20. Qiu J: **Covert coronavirus infections could be seeding new outbreaks.** *Nature* 2020.
- 425 21. Tang B, Wang X, Li Q, Bragazzi NL, Tang S, Xiao Y, Wu J: **Estimation of the Transmission**

- 422 **Risk of the 2019-nCoV and Its Implication for Public Health Interventions.** *Journal of*
423 *clinical medicine* 2020, **9**(2).
- 424 22. Zhang C, Wang M: **MRCA time and epidemic dynamics of the 2019 novel coronavirus.**
425 *bioRxiv* 2020.
- 426 23. Li X, Wang W, Zhao X, Zai J, Zhao Q, Li Y, Chaillon A: **Transmission dynamics and**
427 **evolutionary history of 2019-nCoV.** *Journal of medical virology* 2020, **92**(5):501-511.
- 428 24. Shao P, Shan Y: **Beware of asymptomatic transmission: Study on 2019-nCoV prevention**
429 **and control measures based on extended SEIR model.** *bioRxiv* 2020.
- 430 25. Ming W-K, Huang J, Zhang CJP: **Breaking down of healthcare system: Mathematical**
431 **modelling for controlling the novel coronavirus (2019-nCoV) outbreak in Wuhan, China.**
432 2020.
- 433 26. Chen TM, Rui J, Wang QP, Zhao ZY, Cui JA, Yin L: **A mathematical model for simulating**
434 **the phase-based transmissibility of a novel coronavirus.** *Infectious diseases of poverty* 2020,
435 **9**(1):24.
- 436 27. Chen T, Gu H, Leung RK, Liu R, Chen Q, Wu Y, Li Y: **Evidence-Based interventions of**
437 **Norovirus outbreaks in China.** *BMC Public Health* 2016, **16**(1):1072.
- 438 28. Chen T, Ka-Kit Leung R, Liu R, Chen F, Zhang X, Zhao J, Chen S: **Risk of imported Ebola**
439 **virus disease in China.** *Travel medicine and infectious disease* 2014, **12**(6 Pt A):650-658.
- 440 29. Cui J-A, Zhao S, Guo S, Bai Y, Wang X, Chen T: **Global dynamics of an epidemiological**
441 **model with acute and chronic HCV infections.** *Applied Mathematics Letters* 2020, **103**.

- 442 30. Zhao S, Ran J, Yang G, Cao P: **Attach importance to the procedure of deriving**
443 **reproduction numbers from compartmental models: Letter to the editor in response to**
444 **'Seasonality of the transmissibility of hand, foot and mouth disease: a modelling study in**
445 **Xiamen City, China'**. *Epidemiology and infection* 2020, **148**:e62.
- 446 31. Huang Z, Wang M, Qiu L, Wang N, Zhao Z, Rui J, Wang Y, Liu X, Hannah MN, Zhao B, Su Y,
447 Zhao B, Chen T: **Letter to the editor in response to 'Seasonality of the transmissibility of**
448 **hand, foot and mouth disease: a modelling study in Xiamen City, China'**. *Epidemiology*
449 *and infection* 2020, **148**:e61.
- 450 32. Huang Z, Wang M, Qiu L, Wang N, Zhao Z, Rui J, Wang Y, Liu X, Hannah MN, Zhao B, Su Y,
451 Zhao B, Chen T: **Seasonality of the transmissibility of hand, foot and mouth disease: a**
452 **modelling study in Xiamen City, China**. *Epidemiology and infection* 2019, **147**:e327.
- 453 33. Wang Y, Wang Y, Chen Y, Qin Q: **Unique epidemiological and clinical features of the**
454 **emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control**
455 **measures**. *Journal of medical virology* 2020.
- 456 34. Novel Coronavirus Pneumonia Emergency Response Epidemiology T: **[The epidemiological**
457 **characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]**.
458 *Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi* 2020, **41**(2):145-151.
- 459 35. Yang Y, Lu Q, Liu M, Wang Y, Zhang A, Jalali N, Dean N, Longini I, Halloran ME, Xu B,
460 Zhang X, Wang L, Liu W, Fang L: **Epidemiological and clinical features of the 2019 novel**
461 **coronavirus outbreak in China**. 2020.

462

463

464

465

466

467

468

469

470 **Figure legends**

471 **Figure 1 SEIAR model for simulating COVID-19**

472 **Figure 2 Temporal distribution of COVID-19 in Jilin Province, China**

473 **Figure 3 The proportion of disease severity according to gender in Jilin Province, China**

474 **Figure 4 The proportion of disease severity in different age groups in Jilin Province, China**

475 **Figure 5 The fitting results of the SEIAR model and the data of the actual secondary cases of**
476 **COVID-19 cases in Jilin Province, China**

477 **Figure 6 Simulation results of the SEIAR model without intervention and the data of the actual**
478 **secondary cases of COVID-19 cases in Jilin Province, China**

479 **Figure 7 COVID-19 prevalence curve and peak incidence after taking measures at different time**
480 **points in Jilin Province, China**

481

482

483

484

485

486

487

488

489

490 Tables

491 Table 1 The definition and values of parameters in SEIAR model of COVID-19 in Jilin Province,
 492 China

| Parameter | Description | Unit | Value | Parameter source |
|-----------|--|---|--------------------------|------------------|
| β_1 | Infection rate coefficient (before February 19) | Person ⁻¹ ·day ⁻¹ | 6.7865×10 ⁻⁹ | Curve Fitting |
| β_2 | Infection rate coefficient (after February 19) | Person ⁻¹ ·day ⁻¹ | 2.0519×10 ⁻¹⁰ | Curve Fitting |
| k | Coefficient of Transmissibility of A relative to I | 1 | 1 | literature[26] |
| p | Proportion of asymptomatic infections | 1 | 0.04 | Actual data |
| ω | Relative rate of incubation period of I | day ⁻¹ | 0.1 | Actual data |
| ω' | Relative rate of incubation period of A | day ⁻¹ | 0.1 | literature[26] |
| γ | Coefficient of time between onset and admission | day ⁻¹ | 0.33 | Actual data |

| | | | | |
|-----------|------------------------------|-------------------|------|----------------|
| γ' | Infection period coefficient | day ⁻¹ | 0.33 | literature[26] |
| f | Fatality rate | 1 | 0 | Actual data |

493

494

495 **Table 2 Prediction of short-term onset of COVID-19 without intervention**

| Date | Number of cases | Cumulative number of cases | Attack rate |
|---------|-----------------|----------------------------|-------------|
| Feb. 29 | 20 | 356 | 1.32E-05 |
| Mar. 31 | 82 | 1755 | 6.52E-05 |
| Apr. 30 | 313 | 7033 | 2.61E-04 |
| May.31 | 1250 | 28485 | 1.06E-03 |
| Jun.30 | 4742 | 108914 | 4.05E-03 |
| Jul.31 | 18217 | 427535 | 1.59E-02 |

496

497

498 **Table 3 Prevalence of COVID-19 after comprehensive intervention at different time points**

| Time for comprehensive intervention | Cumulative number of cases | Attack rate | Peak date | Peak incidence | Outbreak duration |
|-------------------------------------|----------------------------|-------------|-----------|----------------|-------------------|
| D175 | 170197 | 0.63% | Jul. 5 | 5911 | 8 month |
| D200 | 510848 | 1.90% | Jul. 30 | 17462 | 9 month |
| D225 | 1471201 | 5.47% | Aug. 24 | 48043 | 10 month |
| D250 | 3805023 | 14.14% | Sept. 18 | 109787 | 11 month |
| D275 | 7892257 | 29.33% | Oct. 13 | 171253 | 12 month |
| D300 | 12193645 | 45.32% | Oct. 22 | 177011 | 13 month |
| D325 | 14939812 | 55.52% | Oct. 22 | 177011 | 14 month |
| D350 | 16235738 | 60.34% | Oct. 22 | 177011 | 15 month |
| D375 | 16775568 | 62.35% | Oct. 22 | 177011 | 16 month |
| D650 | 17129367 | 63.66% | Oct. 22 | 177011 | 22 month |

499

500